Inno-Gene S.A.

Equities

IGN

PLINNGN00015

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
1.81 ^PLN	+1.69%		+6.47%	-17.73%

Feb. 14	Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 14	Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2021

February 14, 2022 at 02:12 pm EST

Inno-Gene S.A. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was PLN 29.91 million compared to PLN 4.68 million a year ago. Net income was PLN 7.69 million compared to PLN 1.57 million a year ago.

Latest news about Inno-Gene S.A.

Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Inno-Gene S.A. announced that it expects to receive PLN 1 million in funding	Jan. 10	CI
Inno-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Inno-Gene S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Inno-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-07	CI
Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-07	CI
Inno-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Ignitis to Secure $119 Million Credit Line to Bolster Capital Amid Higher Energy Prices	22-10-25	MT
Naturativ Sp. z o.o. announced that it has received PLN 0.49995 million in funding from Inno-Gene S.A.	22-08-17	CI
Inno-Gene S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Inno-Gene S.A. acquired additional 10.72% minority stake in Naturativ for PLN 0.01 million.	22-05-31	CI
Inno-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Ignitis Expects Debt Repayment, Compensation as Lithuania Enacts Anti-Inflation Measures	22-04-04	MT
Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-14	CI
Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-14	CI
Ignitis Grupé Unit Acquires Wind Farm in Poland	21-12-21	MT
Ignitis Secures Polish License to Operate Wind Farm	21-12-07	MT
Inno-Gene S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Inno-Gene S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Inno-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-15	CI
Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-02-14	CI
CovidVax sp. Z oo announced that it expects to receive PLN 10 million in funding from Inno-Gene S.A.	20-10-05	CI
Inno-Gene S.A. acquired unknown stake in INNGEN SA for PLN 0.01 million.	20-08-19	CI

Chart Inno-Gene S.A.

Duration

Period

More charts

Company Profile

Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA's portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
INNO-GENE S.A.	-17.73%	2.87M
EXACT SCIENCES CORPORATION	-36.44%	8.68B
GUARDANT HEALTH, INC.	-3.29%	3.2B
IOVANCE BIOTHERAPEUTICS, INC.	+19.31%	2.71B
BGI GENOMICS CO., LTD.	-18.71%	2.04B
VERACYTE, INC.	-22.03%	1.64B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+64.58%	1.43B
CAREDX, INC	+34.58%	841M
SEEGENE, INC.	-7.42%	718M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-25.51%	538M

Bio Diagnostics & Testing